Assessing outcomes of health and medical research: do we measure what counts or count what we can measure? by Wells, Robert & Whitworth, Judith
BioMed Central
Australia and New Zealand Health 
Policy
ssOpen AcceCommentary
Assessing outcomes of health and medical research: do we measure 
what counts or count what we can measure?
Robert Wells*† and Judith A Whitworth†
Address: Menzies Centre for Health Policy, The Australian National University, Canberra, ACT, 2601, Australia
Email: Robert Wells* - robert.wells@anu.edu.au; Judith A Whitworth - judith.whitworth@anu.edu.au
* Corresponding author    †Equal contributors
Abstract
Governments world wide are increasingly demanding outcome measures to evaluate research
investment. Health and medical research outputs can be considered as gains in knowledge, wealth
and health. Measurement of the impacts of research on health are difficult, particularly within the
time frames of granting bodies. Thus evaluations often measure what can be measured, rather than
what should be measured. Traditional academic metrics are insufficient to demonstrate societal
benefit from public investment in health research. New approaches that consider all the benefits of
research are needed.
Background
Health and medical research in Australia received a very
welcome boost in investment in the latest Common-
wealth budget. The use of the word investment reflects the
growing literature on the substantial economic returns to
society from health and medical research (HMR). This is
sometimes described as research 'payback' [1]. In 2003
Access Economics reported that return on investment for
HMR in Australia was around 5-fold and that 'investment
in health research and development surpasses every other
source of rising living standards in our time' [2].
The Macroeconomic Commission on Health [3] con-
cluded that the evidence is overwhelming that invest-
ments in health pay off in controlling disease, improving
productivity, speeding economic growth and fostering
social and political stability.
This notwithstanding, governments world wide are
increasingly asking for outcome measures in the evalua-
tion of research investment and for the justification of
increased investment. Doing it well is no longer enough,
and funding bodies are increasingly looking to objective
ways of assessing the value of research.
In Australia, the Federal Government is planning to intro-
duce a Research Quality Framework (RQF) to measure
both the quality and impact of research undertaken
within universities. As the detail of the RQF is worked
through over coming months much attention will be paid
to the measures of research impact [4].
With this in mind, how should the value of health and
medical research best be measured?
The outputs of health and medical research are often con-
sidered under the headings of knowledge gain, wealth
gain, and health gain [5-8], and it seems self evident that
the latter must be the most important. That being said, the
other two are very much easier to measure, so that any
assessment of research worth runs the risk of falling into
the trap of measuring what we can, not what is important.
Published: 28 June 2007
Australia and New Zealand Health Policy 2007, 4:14 doi:10.1186/1743-8462-4-14
Received: 27 October 2006
Accepted: 28 June 2007
This article is available from: http://www.anzhealthpolicy.com/content/4/1/14
© 2007 Wells and Whitworth; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 3
(page number not for citation purposes)
Australia and New Zealand Health Policy 2007, 4:14 http://www.anzhealthpolicy.com/content/4/1/14Knowledge
Knowledge gain is the least difficult to assess, albeit still
problematic. This is because the outputs (usually publica-
tions) are more proximate to the research performance
and can be quantified, with variable precision, by a variety
of markers, in particular by bibliometrics. Thus numbers
of papers, impact factors of journals, and citations are all
widely used. A number of scholarly analyses have
addressed the strengths, weaknesses and pitfalls of such
approaches but they are relatively robust, at least within
field for aggregated data. More recently new tools have
been developed for bibliometric assessment of individual
researchers, specifically the Hirsch index and its deriva-
tives. Often research income is used as a surrogate, as
judgments on funding usually rely on some measure of
outcome. These measures, and others, as peer recognition,
prizes, named lectures etc, all correlate to a degree (not
surprisingly, as they all purport to measure the same
thing).
But the measures given most weight by granting bodies,
particularly journal impact factor, may not relate well to
the ultimate goal of health and medical research, that is,
health outcomes. John Cade's discovery of lithium for
treatment of manic-depressive illness, unquestionably
one of the greatest findings of the 20th century, both in
relief of suffering (health gain) and cost savings (wealth
gain), was published locally [9] as were some of 2006
Nobel Laureate Barry Marshall's key early papers on Heli-
cobacter (pyloric campylobacter) [10,11].
Journal impact factors are determined inter alia by cita-
tions, but in aggregate, so that they say little about indi-
vidual research papers. Anecdotally some researchers
claim that really original work, which overturns conven-
tional paradigms, is not accepted by 'first rank' journals
and finds its way into less prestigious publications. For
example, Parish's first paper on heparanase which showed
that sulfated sugars could be used to inhibit tumour
metastasis by blocking heparanase action was published
in 1987 in the International Journal of Cancer (impact factor
~ 3) [12]. The paper has been cited many times and under-
pinned development of the anti cancer drug PI-88 that has
already been granted orphan drug status by the US Food
and Drug Administration.
The use of CFSE, a fluorescent dye developed for studying
cell migration and proliferation, was published in Journal
of Immunological Methods (impact factor ~ 1.9) in 1994
[13]. The approach is used in ~20–30% of all cellular
immunology papers currently published, and a Google
search suggests that between 5,000 and 10,000 papers
have been published in which the procedure is used.
The European Journal of Hand Surgery doubled its impact
factor through an editorial review on the vagaries of cita-
tions which quoted its own papers [14].
Wealth
Wealth generation is more difficult to measure. A range of
methodologic approaches to economic assessment of
health research outcome have been described both
nationally and internationally. These include valuing the
direct cost savings from application of research findings,
the economic value of a healthy workforce from improved
healthcare, economic gain from new products and tech-
nologies, and some measurement of social health gain by
placing a monetary value on healthy life [8]. This review
from Brunel University highlights the methologic difficul-
ties associated with impact assessment.
Patents and formation of spin-off companies are widely
used, but are only surrogates. Patents often come to noth-
ing and many spin-offs fail. Given the significant lag time
from development to commercialization for devices and
diagnostics, and the very long time for therapeutic and
preventive agents, wealth generation often occurs years or
decades after the original research, and well outside the
time frame of political decision making, or even of grant-
ing bodies.
In the health context one might ask whether a more real-
istic measure of wealth would identify some metric for
linking savings to the health system from particular dis-
coveries. For example, Kirschner and colleagues reported
that the discovery of lithium treatment for manic-depres-
sive disorders had saved the USA over $145 billion in hos-
pital costs alone [15]. Extrapolating this outcome to
Australia this treatment alone would result in savings in
excess of Australia's national health research investment.
Another legitimate financial measure would be qualifica-
tion of the contribution to economic activity from disease
prevention through effective public health programs.
Countries which have managed to reduce rates of tobacco
consumption have, among other benefits, improved
workforce productivity through reduced absenteeism.
At present there is no accepted way of including impacts
of these measures in a research assessment framework.
Health
Even more vexed, but undeniably most important, is the
question of measuring health outcomes as a product of
research. Given that lag times for research into practice
can be very long, how is it possible to measure outcomes
of investments made in time frames which match those of
policy makers or granting bodies?Page 2 of 3
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Measures that might be used include incorporation of
research into clinical guidelines or systematic reviews of
best practice, generation of such guidelines or systematic
reviews, or contributions to reports (usually government
reports) which inform health policy or practice. But it is
hard to reduce these to metrics, and qualitative rather than
quantitative approaches are needed.
Similarly, the contribution to health gain of research in
health services and health systems and policy are difficult
to measure. For example, the improvement in health out-
comes for stroke victims treated in dedicated stroke clinics
is well documented but system take-up has been poor
[16]. In one sense then the impact of this work has been
poor and it would therefore not rate highly on any meas-
ure of impact.
Finding new measures of research impact
A linear approach to measuring impact that attempts to
take a particular research finding and identify its health
impacts will not meet most situations. In most areas, such
as health services and public health, the potential for sys-
tem impact will only be obvious after analysis of several
studies, such as a Cochrane review, and the impetus for
policy or system change might only come after govern-
ments have been persuaded of the benefits of reallocating
health resources in the appropriate way. In such a scenario
which piece of research legitimately claims the impact: the
original study/ies? The Cochrane review? The policy
'translational' work? If all can have some claim, how is the
impact 'quotient' fairly divided among them?
Conclusion
Traditional academic metrics of research output through
peer-reviewed publications and citations are insufficient
to satisfy society's expectation that public investment in
research results in real benefit to the society. This is partic-
ularly the case for HMR. An approach that takes into
account all the benefits of research outcomes, including
the freeing up of resources from savings on treatment and
other costs, needs to be taken. This approach will require
new metrics which are understood and accepted by soci-
ety and the governments which represent it. It is no longer
enough to measure what we can – we need to measure
what matters.
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